Investor Relations

AVEO Oncology is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide substantial improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development of its therapeutic candidates.

NASDAQ | AVEO (Common Stock)
$0.86 + 0.02
Stock chart for: AVEO.O.  Currently trading at $0.86 with a 52 week high of $3.50 and a 52 week low of $0.80.
02/12/16 12:43 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO to Present at the 18th Annual BIO CEO & Investor ConferenceRead More
AVEO to Present at Biotech Showcase 2016Read More
AVEO and EUSA Pharma Announce Exclusive Licensing Agreement for Tivozanib in EuropeRead More